{"name":"Zhejiang Teruisi Pharmaceutical Inc.","slug":"zhejiang-teruisi-pharmaceutical-inc","ticker":"","exchange":"","domain":"","description":"Zhejiang Teruisi Pharmaceutical Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies, particularly in oncology. The company has a pipeline of five drugs, including a China-approved bevacizumab and a recombinant CD20 monoclonal antibody-MMAE conjugate for injection, both in advanced stages of clinical development.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"China-approved Bevacizumab","genericName":"China-approved Bevacizumab","slug":"china-approved-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TRS003","genericName":"TRS003","slug":"trs003","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"China-approved Bevacizumab","genericName":"China-approved Bevacizumab","slug":"china-approved-bevacizumab","phase":"phase_3","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Recurrent glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"TRS003","genericName":"TRS003","slug":"trs003","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNQ2tJaEpFd203dVplQnRhN3ZxWGRlX0RPTlFOMVo2Rlk3VFY1bmRlSUNIZ29USUhHZTMxY3h6TWZBNWhOcTd4cUNOM3ZBRkF2cUQ4cnotbk0xSUg5S1liSHI2dVhrckVfNlpUbExQWmhhVW9WVzl2MW9DU3QwRUZ1UWFGR3dRWkxIUEZR?oc=5","date":"2025-10-31","type":"patent","source":"Insightace Analytic","summary":"Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for - Insightace Analytic","headline":"Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAwWFVQTW5hQno0MlJDemRTOHlKXzJBeTZzS0g4V2FLeTBnQ2xkeWJBR0V1MFNHVE1XNmlDdTV1WmF4bElxRkRxWUV2SGhXQllHVlJFODlNd3paVDhxbUdlRmtsd2pVRUFYYjA3d3Bn?oc=5","date":"2018-09-25","type":"pipeline","source":"Pharmaceutical Executive","summary":"Antibody-Drug Conjugates in China - Pharmaceutical Executive","headline":"Antibody-Drug Conjugates in China","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}